药品管理法实施条例23年来首次全面修订，儿童药罕见病药迎创新激励

Core Points - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" will be officially implemented on May 15, 2026, marking the first comprehensive revision since its introduction in 2002, aimed at enhancing drug regulation and management [1][3] Group 1: Drug Innovation and Market Exclusivity - The revised regulations introduce a market exclusivity system for pediatric and rare disease medications, providing a maximum exclusivity period of seven years for eligible rare disease treatments, contingent on the commitment to ensure drug supply [3][4] - The regulations emphasize support for drug research and innovation driven by clinical value, encouraging the development and clinical promotion of new drugs [3][5] Group 2: Drug Registration and Quality Management - The regulations establish accelerated registration procedures for breakthrough therapies and clarify the responsibilities of drug marketing authorization holders, including the establishment of quality assurance and pharmacovigilance systems [5][6] - The regulations require regular post-marketing evaluations of drugs and comprehensive assessments of changes in the production process on drug quality [5][6] Group 3: Online Drug Sales and Traditional Chinese Medicine - The regulations clarify the responsibilities of online drug sales platforms, mandating them to establish dedicated institutions and personnel to manage drug transactions and ensure compliance with sales qualifications [7] - The regulations encourage the implementation of quality management standards for traditional Chinese medicine production, with local governments tasked to develop relevant plans [7][8] Group 4: Medical Institutions and Compliance - The regulations support the preparation of pediatric formulations in medical institutions to meet the needs of child patients and detail the management system for these formulations [8] - The regulations stipulate that drugs produced overseas but sold in China must comply with local laws and regulations, ensuring comprehensive regulatory consistency [8]